Y2Solution Acquires HRT Robotics, Enters Robotics Business

Y2Solution announced on June 10 that it has acquired HRT Robotics (hereafter HRT), a company specializing in robot system integration (SI).

HRT is the first official domestic partner of Universal Robots, the world’s leading collaborative robot manufacturer. The company designs and supplies robot automation solutions tailored to the manufacturing environments of its clients. HRT is especially recognized as an automation solutions provider with expertise in integrating control systems, vision cameras, and autonomous mobile robots (AMR). The company is currently developing its own autonomous mobile robot (AMR).

Universal Robots was the first company in the world to commercialize collaborative robots and holds a 40% share of the global market. It is a subsidiary of Teradyne, a Nasdaq-listed company with a market capitalization of approximately 19 trillion KRW, and plays a central role in the global automation ecosystem, including collaborative robots and autonomous mobile robots.

Y2Solution explained that, through this acquisition, it will add robot SI capabilities to its existing power supply unit (PSU) business and enter the industrial collaborative robot and robot integration solutions market. Based on its high-efficiency power module development technology, the company also plans to expand into the field of charging power modules for robots in the future.

Kang Seokhwan, CEO of Y2Solution, stated, "The significance lies in securing core competencies for the implementation of future manufacturing industries, such as smart factories, along with our entry into the robot SI business." He added, "We plan to expand our business scope to include robots, leveraging the synergy from the HRT acquisition." He further emphasized, "We aim to establish ourselves as a company with competitiveness in the fields of charging power modules for robots and SI solutions."

Meanwhile, Y2Solution is conducting global clinical trials for a treatment for dry macular degeneration through its U.S. joint venture LuxaBio. Based on its stable and profitable existing business, the company is focusing on enhancing its mid- to long-term corporate value through its two-track growth strategy in robotics and bio sectors.